Our initial experimental model designed to examine the efficacy of CD16-BB-ζ and CD64-BB-ζ receptor in NK-92MI cells (referred to as NK-92MIhCD16 or NK-92MIhCD64 in the text below; hCD16 denotes humanized CD16, and hCD64 means humanized CD64) was CD20-positive non-Hodgkin's lymphoma (NHL). The gene discussed is FCGR1A; the disease is non-Hodgkin lymphoma.